Cannabis Bioscience International completes patent-related framework for PTSD cannabinoid, psilocybin research

CANNABIS BIOSCIENCE INTL HLDGS

CBIH

0.00

Cannabis Bioscience International Holdings completed patent-related work for PTSD-focused research spanning cannabinoids, psilocybin, formulation systems, therapeutic pathways.
Framework positions cannabinoids for stress-response, sleep, inflammation, emotional regulation research; psilocybin for neuroplasticity, emotional processing, fear-learning, mood studies.
Strategy targets a regulated medical research platform beyond a single condition, aiming to support partnering flexibility and future therapeutic development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606150700NEWSFILECNPR____20260615_301379_1) on June 15, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.